ALSO NOTED: Pharma plant explosions in India, Ireland; Sanofi inks $192M avian flu vaccine deal;

> At least one worker was killed and others seriously injured in two separate pharmaceutical-plant explosions, one at Sirius India Ltd. in Hyderabad, India, and the other at Cordon PharmaChem in Little Island, Ireland. Report | Report

> Sanofi Pasteur announced a $192.5 million contract to provide 38.5 million doses of avian influenza vaccine to the U.S. government. Report

> Australia's drug watchdogs have received a petition to change the Roche antiviral Tamiflu to an over-the-counter drug so that patients can get it quickly enough to be effective. Report

> India's Lupin launched its urinary tract infection treatment Suprax in the U.S. Report

> Bayer got European approval to market its Zevalin lymphoma treatment as an add-on to first-line chemo; previously the drug was only approved as a second-line treatment. Report

> Apotex is suing the FDA for 156 more days of exclusivity on generic Plavix; the company launched its copycat version at risk in 2006, but was stopped by a preliminary injunction 23 days later. Report

> Glenmark Pharma posted fourth-quarter profits of 2.19 billion rupees, triple the same period a year ago. Report

> There's a big sigh of relief coming from Wyeth and Progenics as the FDA approved Relistor, a subcutaneous injection for opioid-induced constipation in patients with advanced illness who are receiving palliative care. Report

> Solvay has made a $278.2 million (€177.6 million) takeover bid for Belgium's Innogenetics. Report

> Another day, another big biotech deal. This time it's Japan's Astellas Pharma, which is paying $760 million for access to CoMentis's Alzheimer's drug. Report

> Which Massachusetts-based biotechs are ripe for buyouts. Report

And Finally... Would patients be better off if doctors stopped accepting insurance? Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.